E.M.G.J. de Jong

European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>

Alexander Nast, Paolo Gisondi, Anthony D. Ormerod et al. · Journal of the European Academy of Dermatology and Venereology · 2015 · 388 citations · Full text

Please Note, Journal Citation Report, Autoimmune Disease +15

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations

Alexander Nast, Catherine Smith, Phyllis I. Spuls et al. · Journal of the European Academy of Dermatology and Venereology · 2020 · 348 citations · Full text

Rheumatology, Euroguiderm Guideline, Systemic Treatment +10

Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study

Marcel Flendrie, Wynand HPM Vissers, M.C.W. Creemers et al. · Arthritis Research & Therapy · 2005 · 256 citations · Full text

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

Alexander Nast, Catherine Smith, Phyllis I. Spuls et al. · Journal of the European Academy of Dermatology and Venereology · 2021 · 196 citations · Full text

β-Defensin-2 Protein Is a Serum Biomarker for Disease Activity in Psoriasis and Reaches Biologically Relevant Concentrations in Lesional Skin

Patrick A.M. Jansen, Diana Rodijk‐Olthuis, Edward J. Hollox et al. · PLoS ONE · 2009 · 171 citations · Full text